A Study to Assess the Effect of AZD5634 on Mucociliary Clearance, Safety, Tolerability and Pharmacokinetic Parameters in Patients With Cystic Fibrosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

9 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-05-30

Study Completion Date

2018-04-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will assess the effect of inhaled AZD5634 on Mucociliary clearance (MCC) in patients with Cystic fibrosis (CF) after single-dose administration.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

To Assess the Safety, Tolerability and Pharmacokinetics of AZD5634 Following Inhaled and Intravenous (IV)Dose Administration

NCT02679729

Cystic Fibrosis

COMPLETED PHASE1

A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis

NCT07201051

Bronchiectasis

NOT_YET_RECRUITING PHASE2

A Study of the Safety and Tolerability of Inhaled SNSP113 in Healthy Subjects and Subjects With Stable Cystic Fibrosis

NCT03309358

Lung Diseases Pulmonary Disease Cystic Fibrosis +13 more

TERMINATED PHASE1

Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis and Chronic Burkholderia Species Infection

NCT01059565

Cystic Fibrosis Burkholderia Infections

COMPLETED PHASE3

A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Bronchiectasis

NCT00769119

Bronchiectasis

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary pharmacodynamic endpoint will be the average whole lung particle clearance between 0 and 60 minutes after administration of aerosolized radiolabelled particles (colloids) at Visits 2 and 3 (%MCC 0-60, whole).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary/Respiratory Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo + AZD5634

Subjects were administered single dose of placebo in period 1 and AZD5634 in period 2.

Group Type EXPERIMENTAL

Placebo

Intervention Type DRUG

Subjects will receive a placebo in either period 1 or period 2 by inhalation.

AZD5634

Intervention Type DRUG

Subjects will receive a single tentative dose of 625 μg of AZD5634 in either period 1 or period 2 by inhalation.

AZD5634 + Placebo

Subjects were administered single dose of AZD5634 in period 1 and placebo in period 2.

Group Type EXPERIMENTAL

Placebo

Intervention Type DRUG

Subjects will receive a placebo in either period 1 or period 2 by inhalation.

AZD5634

Intervention Type DRUG

Subjects will receive a single tentative dose of 625 μg of AZD5634 in either period 1 or period 2 by inhalation.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Placebo

Subjects will receive a placebo in either period 1 or period 2 by inhalation.

Intervention Type DRUG

AZD5634

Subjects will receive a single tentative dose of 625 μg of AZD5634 in either period 1 or period 2 by inhalation.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Provision of signed and dated written informed consent prior to any study-specific procedures.
2. Male or female patients aged 18-60 years old inclusive.
3. Diagnosed of CF at Screening as evidenced in medical records by one of the following criteria:

1. sweat chloride ≥ 60 mmol/L
2. presence of 2 mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene.
4. Chronic sinopulmonary disease or pancreatic insufficiency.
5. FEV1measurement at Screening ≥ 40% of the predicted normal value of age, height, gender, and race.
6. Stable CF regimen for at least 2 months before Screening.
7. Body mass index (BMI) between 15-30 kg/m2 inclusive.
8. Female patients are not pregnant and do not plan to become pregnant during the study, are not lactating, or are of non-childbearing potential. Females of childbearing potential must provide a negative serum pregnancy test and have a date of last menstruation consistent with non-pregnancy, negative urine pregnancy tests at each visit, and must be using at least one highly effective method of contraception.
9. Ability of the patient to correctly perform the inhalation procedure after training during the Screening Visit.

Exclusion Criteria

1. Had a pulmonary exacerbation requiring change in antibiotics and/or hospitalization within 28 days before the first dose of Investigational product.
2. History of lung transplant or any other transplantation.
3. Currently being treated with ivacaftor monotherapy at Screening or received ivacaftor monotherapy within 30 days before Screening.
4. History of severe allergy/hypersensitivity or ongoing clinically significant allergy/hypersensitivity, as judged by the Investigator, to drugs in a similar class to AZD5634.
5. History or presence of hepatic cirrhosis.
6. Creatinine clearance \<60 mL/min/m2 using the Cockroft-Gault Equation.
7. Liver function test results \>2x upper limit of normal (aspartate aminotransferase \[AST\], alanine aminotransferase \[ALT\], gamma-glutamyl transpeptidase \[GGT\], or bilirubin)
8. History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the patient at risk because of participation in the study, or influence the results or the patient's ability to participate in the study.
9. Received treatment with the following medications within the 3 weeks before Screening: strong or moderate Cytochrome P450 (CYP) 3A inhibitors, as classified by the Food and Drug Administration (FDA).
10. Likely to require treatment during the study with drugs not permitted by the study protocol.
11. Any clinically significant abnormalities in clinical chemistry, hematology, or urinalysis results.
12. Serum potassium levels are outside the normal range (3.5-5.1 mmol/L).
13. Serum sodium levels \<135 mmol/L.
14. Abnormal vital signs, after 5 minutes rest, at Screening or Visit 2 (seated or supine; position should be consistent for a given patient at both visits), defined as any of the following:

* Systolic blood pressure (B.P) \< 90 or ≥ 150 mmHg
* Diastolic B.P \< 45 or ≥ 90 mmHg
* Pulse rate \< 45 or \>110 beats/minute
15. Any clinically significant abnormalities in rhythm, conduction, or morphology of the resting ECG and any clinically significant abnormalities in the 12-lead ECG, as considered by the Investigator, that may interfere with the interpretation of corrected ECG interval measured from the onset of the QRS complex to the offset of the T wave (QTc) interval changes.
16. QTc prolongation defined as QT interval corrected for heart rate using Fridericia's formula (QTcF) \>450 ms.
17. ECG interval measured from the onset of the P wave to the onset of the QRS complex (PR/PQ) interval prolongation (\>240 ms), intermittent second or third degree atrioventricular (AV) block, or AV dissociation.
18. Persistent or intermittent complete bundle branch block (BBB) with ECG interval measured from the onset of the QRS complex to the J point (QRS) \>120 ms or evidence of pre-excitation.

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No